Current stock page

Stock Analysis

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis

Xeris Biopharma Holdings, Inc. (XERS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

XERS Stock Analysis Summary

Xeris Biopharma Holdings, Inc. (XERS) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 98/100. Risk is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

XERS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$16.66
AIQ Score78/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$3.01B
P/E Ratio (TTM)-415.46
Forward P/E—
EPS (Q3 FY2026)$0.06
Revenue (Q3 FY2026)$107.23M
Dividend Yield (TTM)0.00%
Beta0.07
Volume3.4M
52-week range$5.25-$16.88
RSI 1485.42
50-Day SMA$10.40
200-Day SMA$7.83
Analyst Price Target$15.00
Next EarningsMar 1, 2027
As of Nov 13, 2026 · Market close

XERSXeris Biopharma Holdings, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$16.66+$0.01 (+0.06%)

Latest quote

  • Momentum
    98
  • Value
    68
  • Quality
    71
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

XERS Stock Analysis Summary

Xeris Biopharma Holdings, Inc. (XERS) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 98/100. Risk resilience is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, XERS has AIQ Score of 78/100 with Momentum base of 98/100 and fading Risk resilience at 55/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (98/100) leads while Risk resilience (55/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.06% stock move · XERS classified in Biotechnology.

Current Evidence

BullishXERS is in a bullish AIQ regime; Momentum is the strongest visible factor at 98/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is XERS Bullish or Bearish Right Now?

XERS currently has a bullish overall setup. Momentum is the strongest factor at 98/100, while Risk Resilience is weakest at 55/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 71/100.
  • - Momentum is constructive at 98/100.
  • - Price is +60.12% above its 50-day SMA.
  • - Technical consensus has more buy votes than sell votes (37 vs 9).
Bear Case
  • - Analyst target implies -9.96% downside from the latest quote.

Current Consensus

XERS's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 0 neutral, and 9 sell votes. XERS's 14-day RSI is 85.42, which places the stock in an overbought momentum range. XERS's beta is 0.07, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in XERS?

The largest recent change in XERS is Momentum moving up by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+2.0
Quality
+0.0
Risk
+1.0

What Would Change the XERS Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

XERS Decision Framework

Public evidence layers, setup checks, and risk context for Xeris Biopharma Holdings, Inc..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis

Xeris Biopharma Holdings, Inc. has an AIQ Score of 78/100 in a Bullish regime. Momentum is strongest at 98/100. Beta is 0.07, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextXERS is in a Bullish AIQ regime with score 78/100.
Signal ConflictThe primary conflict is that momentum leads at 98/100 while risk lags at 55/100.
Factor EvidenceMomentum 98/100 · Value 68/100 · Quality 71/100 · Risk 55/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 98/100.

TimingPass

Momentum is 98/100 and RSI (14) is 85.4.

Regime fitPass

XERS is in a Bullish regime at 78/100.

Risk controlWait

Risk factor is 55/100 with beta 0.07 and annual volatility 56.97%.

ConflictWait

Current conflict: momentum leads at 98/100 while risk lags at 55/100.

AIQ Score
78/100
Price
$16.66
Beta
0.07
RSI (14)
85.4

XERS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

XERS Fundamentals

XERS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$107.23M
Net income
$11.29M
Free cash flow
$35.31M
View full XERS fundamental analysis

XERS Technical Analysis

XERS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
85.42
Price vs SMA-50
+60.12%
View full XERS technical analysis

XERS Stock Catalysts

Track XERS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 1, 2027
Analyst target
$15.00
News items
0
View XERS earnings and stock catalysts

XERS Dividend Analysis

XERS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View XERS dividend history and analysis

XERS Financial Data

XERS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$107.23M
EPS
$0.06
Periods
8
View XERS financials

XERS Risk Analysis

XERS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.07
Risk score
55/100
1Y volatility
56.97%
View XERS risk analysis

XERS Stock News

XERS stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read XERS stock news

XERS vs Biotechnology Peers

Current peer cohort: XERS · ZBIO · ZYME · ABCL · ABSI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
XERS
Current stock
78/10068/10098/10055/1001.6756.97%Current
ZBIO
Zenas BioPharma, Inc.
47/10033/10078/10039/1000.2695.33%XERS vs ZBIO
ZYME
Zymeworks Inc.
68/10066/10078/10061/1000.8454.03%XERS vs ZYME
ABCL
AbCellera Biologics Inc.
64/10047/10089/10034/1001.7385.28%XERS vs ABCL
ABSI
Absci Corporation
53/100—85/10030/1001.58104.15%XERS vs ABSI
Pairwise Compare links: ZBIO · ZYME · ABCL · ABSIXERS vs ZBIOXERS vs ZYMEXERS vs ABCLXERS vs ABSICompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a XERS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for XERS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-415.46
As of Nov 13, 2026
Revenue growth
44.16%
Gross margin
84.44%
Current debt / equity
4.63
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$107.23M
Quarter net income
$11.29M
Quarter free cash flow
$35.31M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
85.42
MACD
1.74

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
55/100
Beta
0.07
Annual volatility
56.97%
Max drawdown
-34.93%

XERS Stock FAQ

What is XERS stock price today?

Xeris Biopharma Holdings, Inc.'s current stock price is $16.66. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is XERS bullish or bearish right now?

XERS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is XERS's market cap?

XERS's market cap is $3.01B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is XERS's current P/E ratio?

XERS's current P/E ratio is -415.46 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is XERS's RSI?

XERS's 14-day RSI is 85.42 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is XERS above its 50-day and 200-day moving averages?

XERS is 60.12% from its 50-day SMA and 112.76% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is XERS's next earnings date?

XERS's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does XERS pay a dividend?

XERS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.